Trial Profile
A Randomized, Double-Blind Controlled Comparison of NRX-101 to Lurasidone for Adults With Bipolar Depression and Subacute Suicidal Ideation or Behavior
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Cycloserine/lurasidone (Primary) ; Lurasidone
- Indications Bipolar depression; Suicidal ideation
- Focus Registrational; Therapeutic Use
- Sponsors NeuroRX; NRx Pharmaceuticals
- 08 Apr 2024 According to a NRx Pharmaceuticals media release, company achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101. With positive data from this study and FDA comment, NRx becomes eligible to receive the balance of its first milestone (an additional $4 million) from partners Alvogen, Inc. and Lotus Pharmaceuticals, Inc.
- 28 Mar 2024 According to a NRx Pharmaceuticals media release, final Data Lock expected this week with Top line data expected in April 2024.
- 04 Mar 2024 Status changed from active, no longer recruiting to completed as per NRx Pharmaceuticals media release